The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.

Houin, Georges; Brunner, Felix; Nebout, T; Cherfaoui, Maya; Lagrue, G; Tillement, J P

doi:10.1111/j.1365-2125.1983.tb02157.x

Cited by 37 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the oral administration of a single 200 mg dose to humans, C max range between 5 and 6 μ g/mL with a t 1/2 of 13–16 h (Welling et al. , 1977; Houin et al. , 1983).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals

Womble

Giguère

Lee

2007

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The objective of this study was to determine the disposition of orally administered doxycycline in foals. Six healthy 4- to 8-week-old foals were used. Doxycycline was administered to each foal via the intragastric (IG) route at dosages of 10 and 20 mg/kg, in a cross-over design. After the first 10 mg/kg dose, five additional doses were administered at 12-h intervals. A microbiological assay was used to measure doxycycline activity in serum, urine, peritoneal fluid, synovial fluid, cerebrospinal (CSF), pulmonary epithelial lining fluid (PELF), and bronchoalveolar (BAL) cells. Following administration at 10 mg/kg, mean+/-SD time to peak serum doxycycline activity (tmax) was 3.0+/-1.2 h, maximum serum activity (Cmax) was 2.54+/-0.27 microg/mL, and terminal half-life (t1/2) was 8.5+/-2.8 h. Administration at a dose of 20 mg/kg resulted in a significantly longer tmax (5.5+/-1.8 h) as well as a tendency toward higher Cmax (2.89+/-0.33 microg/mL) and longer t1/2 (11.9+/-2.6 h). After multiple IG doses, doxycycline activity in CSF was significantly lower than concurrent serum activity, whereas peritoneal fluid, synovial fluid, and BAL cell doxycycline activity was similar to concurrent serum activity. Doxycycline activity in urine and PELF was significantly higher than that found at other sites. Oral administration at a dosage of 10 mg/kg every 12 h would maintain serum, PELF, and BAL cell activity above the minimum inhibitory concentrations of Rhodococcus equi, beta-hemolytic streptococci, and other susceptible bacterial pathogens for the entire dosing interval.

show abstract

“…After the oral administration of a single 200 mg dose to humans, C max range between 5 and 6 μ g/mL with a t 1/2 of 13–16 h (Welling et al. , 1977; Houin et al. , 1983).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals

Womble

Giguère

Lee

2007

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…In this respect, it is centration curve 27 that falls below 1 g/ml after approximately 24 h for minocycline 30 and 50 h for doxycycline. 32 interesting to realise that anhydrotetracycline results in a shorter delay in resumption of tRP activity than minocycThis, together with the higher tissue to plasma concentration ratio of doxycycline and minocycline, ensures that line or doxycycline, despite having much higher K A for tetR compared with these derivatives. Moreover, tRP the expression of a given gene can be kept switched off …”

mentioning

confidence: 99%

Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues

et al. 1997

View full text Add to dashboard Cite

The tetracycline-regulatable system (TRS) has become a that, at 1000 ng/ml, all the analogues have similar widely adopted tool for modification of gene expression efficiencies in down-regulating the system in a given time. and analysis of gene function in mammalian cells, plantsIn contrast, following the removal of the analogues, there and transgenic animals. We have studied the potential is a temporal, dose-dependent delay in resumption of the application of the TRS in gene therapy, using a single vectRP activity. The time taken for resumption of near-optimal tor containing both the tetracycline-controlled transactivtRP activity is approximately 48 h for tetracycline, 144 h for ator (tTA) and the tTA-responsive promoter (tRP) transcribanhydrotetracycline, 192 h for minocycline and 216 h for ing mouse GM-CSF. Stable 293 cells established using doxycycline when cells were pretreated with 1000 ng/ml of this vector were used to study the kinetics of the TRS in these antibiotics. This property of the analogues can be response to various tetracycline analogues. Doseemployed in planning a desired course of transgene reguresponse studies show that doxycycline is the most potentlation. analogue in abolishing tTA activity. Kinetic studies indicate

show abstract

“…The t'/2 values of tetracycline, demeclocycline and oxytetracycline are prolonged in patients with renal dysfunction as they are primarily excreted unchanged in the urine (Saivin & Houin 1988). Although t'/2 values of doxycycline and minocycline may be slightly prolonged in renal failure, AVC and CL are not significantly altered Heaney & Eknoyan 1978;Houin et al 1983b;Sklenar et al 1977). Only Bernard and colleagues (1971) reported a greatly prolonged mean minocycline t,;, in patients with chronic renal failure when compared with healthy volunteers (30.3 vs 13.7h.…”

Section: Tetracyclinesmentioning

confidence: 97%

Clinical Pharmacokinetics of Antibiotics in Patients with Impaired Renal Function

Peter

Redic-Kill

Halstenson

1992

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Many antibiotics are eliminated renally and dosage adjustments are commonly made in patients with renal insufficiency. This is a critical review of antibiotic pharmacokinetics in patients with various degrees of renal function. Detailed information regarding pharmacokinetic alterations with specific antibiotics or antibiotic classes has been compiled and tabulated. From pharmacokinetic evidence, recommendations for dosage adjustments of antibiotics are supplied. The criteria used for assigning rating levels to specific pharmacokinetic articles as well as the grading system for dosage adjustments are outlined. In addition, a basic review of pharmacokinetic alterations in renal failure and factors affecting the removal of drugs by haemodialysis is included.

show abstract

The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.

Cited by 37 publications

References 10 publications

Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals

Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals

Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues

Clinical Pharmacokinetics of Antibiotics in Patients with Impaired Renal Function

Contact Info

Product

Resources

About